- Home
- SEED vs CARA Comparison
SEED vs CARA Comparison
Compare SEED & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- CARA
- Stock Information
- Founded
- SEED 1997
- CARA 2004
- Country
- SEED China
- CARA United States
- Employees
- SEED N/A
- CARA N/A
- Industry
- SEED Farming/Seeds/Milling
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- CARA Health Care
- Exchange
- SEED Nasdaq
- CARA Nasdaq
- Market Cap
- SEED 17.1M
- CARA 16.7M
- IPO Year
- SEED N/A
- CARA 2014
- Fundamental
- Price
- SEED $2.11
- CARA $0.25
- Analyst Decision
- SEED
- CARA Hold
- Analyst Count
- SEED 0
- CARA 3
- Target Price
- SEED N/A
- CARA $1.00
- AVG Volume (30 Days)
- SEED 20.9K
- CARA 1.6M
- Earning Date
- SEED 12-31-2024
- CARA 11-14-2024
- Dividend Yield
- SEED N/A
- CARA N/A
- EPS Growth
- SEED N/A
- CARA N/A
- EPS
- SEED 1.21
- CARA N/A
- Revenue
- SEED $16,516,031.00
- CARA $8,686,000.00
- Revenue This Year
- SEED N/A
- CARA N/A
- Revenue Next Year
- SEED N/A
- CARA N/A
- P/E Ratio
- SEED $1.84
- CARA N/A
- Revenue Growth
- SEED 64.93
- CARA N/A
- 52 Week Low
- SEED $1.37
- CARA $0.23
- 52 Week High
- SEED $6.38
- CARA $1.15
- Technical
- Relative Strength Index (RSI)
- SEED 30.82
- CARA 41.07
- Support Level
- SEED $2.41
- CARA $0.24
- Resistance Level
- SEED $2.65
- CARA $0.30
- Average True Range (ATR)
- SEED 0.18
- CARA 0.02
- MACD
- SEED -0.04
- CARA -0.00
- Stochastic Oscillator
- SEED 1.54
- CARA 40.45
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.